Today, Venture Global, Inc. (NYSE: VG) announced that its subsidiary Calcasieu Pass Funding, LLC (the “Company”), which indirectly controls the Calcasieu Pass project, entered into a $1,750,000,000 senior secured, term loan B credit facility (the “Facility”). Venture Global used a portion of the proceeds from the Facility to redeem, in full, the preferred equity interests of the Company that were previously issued to Stonepeak Bayou Holdings II LP. “We’re very pleased to successfully close th...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented final overall survival data from its pivotal Phase 3 ROSELLA trial of Lifyorli™ (relacorilant) combined with the chemotherapeutic agent nab-paclitaxel in patients with platinum-resistant ovarian cancer in a late-breaking ...